Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadj...

Descripción completa

Detalles Bibliográficos
Autores principales: Boucher, Yves, Kumar, Ashwin S., Posada, Jessica M., Gjini, Evisa, Pfaff, Kathleen, Lipschitz, Mikel, Lako, Ana, Duda, Dan G., Rodig, Scott J., Hodi, F. Stephen, Jain, Rakesh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242049/
https://www.ncbi.nlm.nih.gov/pubmed/34188163
http://dx.doi.org/10.1038/s41698-021-00197-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242049/
https://www.ncbi.nlm.nih.gov/pubmed/34188163
http://dx.doi.org/10.1038/s41698-021-00197-w

Ejemplares similares